{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:37:15Z","timestamp":1777923435655,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,2]]},"DOI":"10.7759\/cureus.87188","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:25:21Z","timestamp":1751498721000},"source":"Crossref","is-referenced-by-count":1,"title":["Assessing the Safety of Semaglutide and Tirzepatide in Black and Asian Populations: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Pulwasha","family":"Iftikhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chander P","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sri Ratna Divya","family":"Nanduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minahil","family":"Ramzan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna Sai Kiran","family":"Sakalabaktula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24037","article-title":"The association between weight loss medications and cardiovascular complications","volume":"32","author":"Baser O","year":"2024","unstructured":"Baser O, Samayoa G, Rodchenko K, Isenman L, Baser E, Yapar N. The association between weight loss medications and cardiovascular complications. Obesity (Silver Spring). 2024, 32:1401-9. 10.1002\/oby.24037","journal-title":"Obesity (Silver Spring)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0668-z","article-title":"Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist","volume":"57","author":"Hall S","year":"2018","unstructured":"Hall S, Isaacs D, Clements JN. Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clin Pharmacokinet. 2018, 57:1529-38. 10.1007\/s40262-018-0668-z","journal-title":"Clin Pharmacokinet"},{"key":"ref3","unstructured":"Highlights of prescribing information. (2022). Accessed. May 20, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck MA","year":"2022","unstructured":"Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022, 21:169. 10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas JP","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021, 385:503-15. 10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra MK","year":"2022","unstructured":"Mahapatra MK, Karuppasamy M, Sahoo BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord. 2022, 23:521-39. 10.1007\/s11154-021-09699-1","journal-title":"Rev Endocr Metab Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12051124","article-title":"An assessment of semaglutide safety based on real-world data: from popularity to spontaneous reporting in EudraVigilance database","volume":"12","author":"Butuca A","year":"2024","unstructured":"Butuca A, Dobrea CM, Arseniu AM, et al.. An assessment of semaglutide safety based on real-world data: from popularity to spontaneous reporting in EudraVigilance database. Biomedicines. 2024, 12:10.3390\/biomedicines12051124","journal-title":"Biomedicines"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27134315","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review","volume":"27","author":"Chavda VP","year":"2022","unstructured":"Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022, 27:10.3390\/molecules27134315","journal-title":"Molecules"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2018.0070","article-title":"Asian subpopulations may exhibit greater cardiovascular benefit from long-acting glucagon-like peptide 1 receptor agonists: a meta-analysis of cardiovascular outcome trials","volume":"43","author":"Kang YM","year":"2019","unstructured":"Kang YM, Cho YK, Lee J, et al.. Asian subpopulations may exhibit greater cardiovascular benefit from long-acting glucagon-like peptide 1 receptor agonists: a meta-analysis of cardiovascular outcome trials. Diabetes Metab J. 2019, 43:410-21. 10.4093\/dmj.2018.0070","journal-title":"Diabetes Metab J"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.025545","article-title":"Racial and ethnic disparities in financial barriers among overweight and obese adults eligible for semaglutide in the United States","volume":"11","author":"Lu Y","year":"2022","unstructured":"Lu Y, Liu Y, Krumholz HM. Racial and ethnic disparities in financial barriers among overweight and obese adults eligible for semaglutide in the United States. J Am Heart Assoc. 2022, 11:e025545. 10.1161\/JAHA.121.025545","journal-title":"J Am Heart Assoc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.890","article-title":"Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?","volume":"9","author":"Olafuyi O","year":"2021","unstructured":"Olafuyi O, Parekh N, Wright J, Koenig J. Inter-ethnic differences in pharmacokinetics-is there more that unites than divides?. Pharmacol Res Perspect. 2021, 9:e00890. 10.1002\/prp2.890","journal-title":"Pharmacol Res Perspect"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01632-4","article-title":"Correction to: Comparative efficacy and safety of tirzepatide in Asians and non-Asians with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"15","author":"Cui Y","year":"2024","unstructured":"Cui Y, Yao J, Qiu X, Guo C, Kong D, Dong J, Liao L. Correction to: Comparative efficacy and safety of tirzepatide in Asians and non-Asians with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Ther. 2024, 15:2443. 10.1007\/s13300-024-01632-4","journal-title":"Diabetes Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587","article-title":"Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial","volume":"10","author":"Kadowaki T","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U, et al.. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an East Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022, 10:193-206. 10.1016\/S2213-8587","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.02.017","article-title":"African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development","volume":"17","author":"Rajman I","year":"2017","unstructured":"Rajman I, Knapp L, Morgan T, Masimirembwa C. African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development. EBioMedicine. 2017, 17:67-74. 10.1016\/j.ebiom.2017.02.017","journal-title":"EBioMedicine"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02536-8","article-title":"A phase 1 multiple dose study of tirzepatide in Chinese patients with type 2 diabetes","volume":"40","author":"Feng P","year":"2023","unstructured":"Feng P, Sheng X, Ji Y, et al.. A phase 1 multiple dose study of tirzepatide in Chinese patients with type 2 diabetes. Adv Ther. 2023, 40:3434-45. 10.1007\/s12325-023-02536-8","journal-title":"Adv Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14952","article-title":"Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme)","volume":"25","author":"Kiyosue A","year":"2023","unstructured":"Kiyosue A, Dunn JP, Cui X, Hickey A, Hirase T, Imaoka T, Heine RJ. Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme). Diabetes Obes Metab. 2023, 25:1056-67. 10.1111\/dom.14952","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00188-7","article-title":"Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial","volume":"10","author":"Inagaki N","year":"2022","unstructured":"Inagaki N, Takeuchi M, Oura T, et al.. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022, 10:623-33. 10.1016\/S2213-8587(22)00188-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(22)00187-5","article-title":"Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial","volume":"10","author":"Kadowaki T","year":"2022","unstructured":"Kadowaki T, Chin R, Ozeki A, et al.. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022, 10:634-44. 10.1016\/s2213-8587(22)00187-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02344-1","article-title":"Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial","volume":"29","author":"Gao L","year":"2023","unstructured":"Gao L, Lee BW, Chawla M, et al.. Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023, 29:1500-10. 10.1038\/s41591-023-02344-1","journal-title":"Nat Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.06.020","article-title":"Cardiovascular impact of race and ethnicity in patients with diabetes and obesity","volume":"78","author":"Joseph JJ","year":"2021","unstructured":"Joseph JJ, Ortiz R, Acharya T, Golden SH, L\u00f3pez L, Deedwania P. Cardiovascular impact of race and ethnicity in patients with diabetes and obesity. J Am Coll Cardiol. 2021, 78:2471-82. 10.1016\/j.jacc.2021.06.020","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.7570\/jomes22067","article-title":"Efficacy and safety of tirzepatide in type 2 diabetes and obesity management","volume":"32","author":"Sinha R","year":"2023","unstructured":"Sinha R, Papamargaritis D, Sargeant JA, Davies MJ. Efficacy and safety of tirzepatide in type 2 diabetes and obesity management. J Obes Metab Syndr. 2023, 32:25-45. 10.7570\/jomes22067","journal-title":"J Obes Metab Syndr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13773","article-title":"Efficacy and safety of once-weekly semaglutide in Japanese individuals with type\u20092 diabetes by baseline age and body mass index","volume":"13","author":"Yabe D","year":"2022","unstructured":"Yabe D, Yamada Y, Kaku K, Nishida T, Sato T, Seino Y. Efficacy and safety of once-weekly semaglutide in Japanese individuals with type\u20092 diabetes by baseline age and body mass index. J Diabetes Investig. 2022, 13:1161-74. 10.1111\/jdi.13773","journal-title":"J Diabetes Investig"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz072","article-title":"Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials","volume":"105","author":"DeSouza C","year":"2020","unstructured":"DeSouza C, Cariou B, Garg S, Lausvig N, Navarria A, Fonseca V. Efficacy and safety of semaglutide for type 2 diabetes by race and ethnicity: a post hoc analysis of the SUSTAIN trials. J Clin Endocrinol Metab. 2020, 105:10.1210\/clinem\/dgz072","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.27258","article-title":"Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes","volume":"7","author":"Chuang MH","year":"2024","unstructured":"Chuang MH, Chen JY, Wang HY, Jiang ZH, Wu VC. Clinical outcomes of tirzepatide or GLP-1 receptor agonists in individuals with type 2 diabetes. JAMA Netw Open. 2024, 7:e2427258. 10.1001\/jamanetworkopen.2024.27258","journal-title":"JAMA Netw Open"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101940","article-title":"Ethnic\/racial and geographic disparities on major cardiovascular events in glucagon-like peptide-1 receptor agonists trials: a meta-analysis","volume":"48","author":"Lavalle Cobo A","year":"2023","unstructured":"Lavalle Cobo A, Masson W, Lobo M, Barbagelata L, Forte E, Corral P, Nogueira JP. Ethnic\/racial and geographic disparities on major cardiovascular events in glucagon-like peptide-1 receptor agonists trials: a meta-analysis. Curr Probl Cardiol. 2023, 48:101940. 10.1016\/j.cpcardiol.2023.101940","journal-title":"Curr Probl Cardiol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05962-z","article-title":"Socioeconomic aspects of incretin-based therapy","volume":"66","author":"Karagiannis T","year":"2023","unstructured":"Karagiannis T, Bekiari E, Tsapas A. Socioeconomic aspects of incretin-based therapy. Diabetologia. 2023, 66:1859-68. 10.1007\/s00125-023-05962-z","journal-title":"Diabetologia"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.16290","article-title":"Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients with heart failure and diabetes","volume":"6","author":"Essien UR","year":"2023","unstructured":"Essien UR, Singh B, Swabe G, et al.. Association of prescription co-payment with adherence to glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor therapies in patients with heart failure and diabetes. JAMA Netw Open. 2023, 6:e2316290. 10.1001\/jamanetworkopen.2023.16290","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/371782-assessing-the-safety-of-semaglutide-and-tirzepatide-in-black-and-asian-populations-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T23:25:22Z","timestamp":1751498722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/371782-assessing-the-safety-of-semaglutide-and-tirzepatide-in-black-and-asian-populations-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.87188","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}